Navigation Links
Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
Date:4/7/2008

LA JOLLA, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) announced today that based on the U.S. Food and Drug Administration's ("FDA") review of its Phase 3 submission the Company can initiate its Phase 3 clinical program for its novel topical cream based non-steroidal anti-inflammatory drug ("NSAID"), Ketotransdel(TM). Transdel Pharmaceuticals is a specialty pharmaceutical company pursuing the development and commercialization of non-invasive topically administered medications.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "I am pleased to announce that the FDA has reviewed our February 7, 2008 FDA submission and has stated that it is safe to proceed with the Phase 3 program. The FDA also noted that there are no clinical hold issues and provided comments regarding the registration requirements of our lead drug. We will continue our discussions with the FDA regarding the final product approval requirements." Dr. Singh continued, "Advancing into Phase 3 clinical studies for Ketotransdel marks a significant milestone for the Company. Our dedicated and committed team is focused on successfully advancing our topical drug to FDA approval."

Based on industry estimates, the market for NSAIDs and Cox-2 inhibitors exceeds $6 billion per year; more than 30 million people worldwide use NSAIDs daily. Due to the recognition of known risks associated with orally administered NSAIDs, including cardiovascular, gastrointestinal and other medical complications, and the decline in the use of Cox-2 inhibitors because of safety concerns, Transdel believes that there is a significant demand for topical pain management products such as Ketotransdel. Moreover, the Company expects that Ketotransdel, if approved by the FDA, could become the first topical NSAID cream product in the United States for acute pain management. The drug could address a significant unmet med
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
2. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
3. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
4. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
5. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
8. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
9. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
10. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...N, Fla., Nov. 25 Ameri...("the Company") is pleased to announce that they h...agement office in Shanghai, China. ,, ASR has b... essential gateway for the development and product...ts for children and adults to be distributed and s...
(Date:11/25/2009)...ADELPHIA, Nov. 25 ERT (N.... McKelvey, the Company,s President and CEO, and K...nt and CFO, are scheduled to present at the 21st A... PM EST on December 1, 2009 in New York City, New ...entation by visiting the Company,s corporate websi...
(Date:11/25/2009)...LM BEACH, Fla., Nov. 25 ...cans, especially the 27 million living with untrea...at happy, says audiologist Cindy Beyer. ,, Dr. ...R ), one of America,s largest hearing care and he...aring loss to stress, frustration, and social isol...
Breaking Medicine Technology:American Scientific Resources Inc. Opens Shanghai Location 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3INHS Brings Health Information Technology Conference to Spokane 52550 1INHS Brings Health Information Technology Conference to Spokane 52550 2Bioheart Announces Acceptance of Marvel 1 Data for Presentation at the Heart Failure Society of America 28HFSA 29 Meeting 52545 1Bioheart Announces Acceptance of Marvel 1 Data for Presentation at the Heart Failure Society of America 28HFSA 29 Meeting 52545 2Bioheart Announces Acceptance of Marvel 1 Data for Presentation at the Heart Failure Society of America 28HFSA 29 Meeting 52545 3Risky driving puts P platers at high danger of crash 52541 1Risky driving puts P platers at high danger of crash 52541 2
...aceuticals,Inc. (Nasdaq: ARNA ) announced today t...e overview of its clinical development and discove... -- ThinkEquity Partners, 5th Annual Growth Confe... at 10:00 a.m. Pacific Time (1:00 p.m. Eastern... Presenting: Jack Lief, Arena,s President and Chie...
... Liver Cancer Conference Sta...y Consulting Firm Retained, NOVATO, Calif., Sept.... "Company") (OTC Bulletin Board:,RPTP.OB) announce...Scientific Officer, will present a poster detailin...al studies of its HepTide(TM) liver targeting,prog...
Other Medicine Technology:Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 2Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences 3Raptor Pharmaceuticals Provides Update of Product Programs 2Raptor Pharmaceuticals Provides Update of Product Programs 3Raptor Pharmaceuticals Provides Update of Product Programs 4Raptor Pharmaceuticals Provides Update of Product Programs 5Raptor Pharmaceuticals Provides Update of Product Programs 6
(Date:11/27/2009)...i-purpose bilingual coloring books designed for ch...ess community to educate - inform parents and chil...sues to Dinosuars to ABC,S and a host of other top...RWEB) November 27, 2009 -- Today’s children ...hem busy any hour of the day, but one of the oldes...
(Date:11/26/2009)... Nov. 27 The diabetes population i...xt 25 years and annual medical spending on the dis...3 billion today, according to a study published in...nal Changing Diabetes ® Program (NCDP), a pr...y a team from the University of Chicago. ,, Acc...
(Date:11/26/2009)...on an emotional rollercoaster, study finds , ...it the fear factor meets the jubilant sports fan. ...ially those who root for the winning team -- enjoy...sted match and victory was in doubt, producing fee... this Thanksgiving weekend as you,re glued to the ...
(Date:11/26/2009)...on Communications announces a highly effective and...rs struggling to make an economic recovery. , ...Flu fears is the type of challenge that could send...ding to Dr. David Benton, business growth expert a...stem – The Rfactor Intensive . “Fea...
(Date:11/25/2009)...f., Nov. 25 Onyx Pharm...that the company will host two investor events in ... 7, 2009 - 9:00 a.m. CT/10:00 a.m. ET ,, Prin...s surrounding carfilzomib in relapsed and/or refra...erican Society of Hematology (ASH) Annual Meeting ...
Breaking Medicine News(10 mins):Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
... announced a,partnership with leading breast care ... These Centers, including breast care physicians f...rship with Sanarus to,increase the awareness and a... of these new Centers prior to,the American Colleg...
...tion on the reauthorization of the State Children,...uld set SCHIP on a solid path over the next,10 yea... Georgetown,University Center for Children and Fam...,CCF analysis, Summary of The Children,s Health In...
...atives International, Inc. ("NAI") (Nasdaq: NAII ... of customized nutritional,supplements, today anno...on,Form 10-K for the fiscal year ended June 30, 20...Form 10-K no later than,October 15, 2007. While N...
...olytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ...g interim results from a U.K. Phase Ia/Ib combina...ients with advanced or metastatic cancers is sched...ological Approaches to Radiosensitisation: Viruses...
...e, study finds , , FRIDAY, Sept. 28 (Healt...weight as a direct cause of high blood pressure. A...ople can bring down blood pressure to healthy leve...sor of medicine at the University of Pavia. He was...
...ia (compulsive hair-pulling) affects between 2-4 %...ildren -- yet remains little,known or understood b...e,Trichotillomania Learning Center (TLC) is drawin... 2007 events include: screenings of the award-winn...
Other Medicine News:Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2Health News:CCF Reviews Contents of SCHIP Reauthorization Bill Legislation Places SCHIP on Solid Path 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 2Health News:Natural Alternatives International, Inc. Announces Late Filing of its Annual Report on Form 10-K, Revenue for Fiscal 2007 and Guidance on First Quarter of Fiscal 2008 3Health News:Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials 2Health News:Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials 3Health News:Weight Loss Can Control Hypertension 2Health News:Weight Loss Can Control Hypertension 3Health News:National Trichotillomania Awareness Week Gives Help and Hope to Hair-Pullers 2
VersaStep™ SHORT Reposable (Reusable Components - Short Length)
VERSASTEP™ Reposable Single Use Instruments
VersaStep™ Plus Instrument
...Open-Step™ single-use system device is compr...nents for creating each access port are also packa...cking cone with 12 mm Step™ cannula assembly...ocking cone with 10/12 mm Reposable Step™ va...
Medicine Products: